Introduction {#s001}
============

I[nflammatory bowel disease]{.smallcaps} (IBD) describes a group of chronic, relapsing autoimmune disorders affecting the small intestine and colon, namely Crohn\'s disease (CD) and Ulcerative Colitis (UC), with developed countries showing the highest incidence of IBD (Wilson and others [@B111]). While IBD patients also have an increased risk of developing colorectal cancer, the fourth most common cause of cancer-related death worldwide (Ferlay and others [@B36]), the chronic nature of IBD contributes to productivity losses by IBD patients and a financial burden on healthcare systems (Burisch and others [@B18]).

The human gastrointestinal (GI) tract extends from the oral cavity to the rectum and includes the small intestine and colon. A single layer of the intestinal epithelial cell (IEC) line, the GI tract, creates a physical barrier, which separates luminal bacteria from the host\'s immune system. An estimated 10^13^ bacteria from over 160 different species colonize the 30 m^2^ absorptive surface of the GI tract in humans (Qin and others [@B87]; Helander and Fändriks [@B45]). The general acceptance by the scientific community that immune responses to specific microbial populations contribute to the pathogenesis of IBD has not only led to a renewed interest in the role of the epithelial barrier in the host defense response, but also triggered an interest in the role of the microbiome. In IBD patients, a significant reduction in microbial diversity has been observed, including a reduction of the Firmicutes genus *Clostridium leptum* in CD patients. Meanwhile, the colitogenic species from the *Streptococcus* and *Haemophilus* phyla is only found in IBD patients (Manichanh and others [@B69]; Palm and others [@B80]). However, not all microbial species are considered pathogenic, with excessive abundance of the *Firmicutes* member *Faecalibacterium prausnitzii* being linked to reduced disease recurrence following ileal resection in CD patients (Sokol and others [@B100]). The increased recognition by the scientific community that immune responses to specific microbial populations contribute to the pathogenesis of IBD has led to a renewed interest in the role of the epithelial barrier in the host defense response.

IBD is associated with chronic inflammation of the bowel, which is thought to develop, in part, from bacteria breaching the epithelial barrier, invading the body, and triggering a perpetuating inflammatory response. A combination of highly specialized IECs and a variety of immune cell populations are critical for maintenance of the integrity of the mucosal GI barrier. Most important among the IECs are goblet cells that secrete mucins, including mucin-2, which comprises the major component of the mucus layer that physically limits the access of commensal bacteria to IECs (Johansson and others [@B49]). Meanwhile, Paneth cells sit adjacent to IEC stem cells at the base of intestinal crypts and secrete antimicrobial peptides, including α-defensins and lysozyme (Wehkamp and others [@B110]). Specialized epithelial microfold (M) cells are situated above lymphoid follicles, such as Peyer\'s patches in the small intestine, and allow immune cells to sample luminal antigens (Mabbott and others [@B68]). In addition, dendritic cells (DCs) can penetrate through tight junctions between IECs to directly sample luminal antigens and process them for subsequent presentation to T and B cells by antigen presentation (Rescigno and others [@B90]). Intraepithelial lymphocytes (IELs), conventional T cells, and γδT cells alongside other immune cells found within the gut or mucosal-associated lymphoid tissue (GALT and MALT, respectively) can secrete cytokines in response to microbial exposure (Wang and others [@B109]). Innate lymphoid cells (ILCs) are present at mucosal surfaces, including the GI tract, and, analogous to the adaptive T helper cell groups (Th1, Th2, and Th17), have been functionally classified as ILC1, ILC2, and ILC3 (Spits and others [@B102]). Through the production of cytokines that induce expression of antimicrobial genes, ILC3 cells, similar to Th17 cells, are of particular importance for the maintennace of intestinal homeostasis during infection and inflammation (Mielke and others [@B71]; Qiu and others [@B89]).

CD is characterized by transmural inflammation that may involve the entire GI tract, although development of disease in the terminal ileum, cecum, colon, and perianal area is most common (Baumgart and Sandborn [@B9]). In contrast, UC is characterized by superficial inflammation affecting the mucosa and submucosa in the colon, with crypt abscesses, pseudopolyps, and ulcers commonly observed (Ordás and others [@B78]). Genome-wide association studies (GWAS) revealed a number of polymorphisms in the JAK/STAT signaling pathway that are associated with IBD susceptibility. Among these, polymorphisms in the Janus Kinase (JAK) family of cytokine receptor-associated cytoplasmic tyrosine kinases, *JAK2* (rs10758669) and *TYK2* (rs280519, rs2304256), as well as in the gene encoding the Jak target protein, Signal Transducer and Activator of Transcription 3 (*STAT3*; rs744166), are associated with CD (Barrett and others [@B8]). Moreover, the *STAT3* polymorphism (rs12948909) is associated with CD and UC, although it still remains unclear how these polymorphisms functionally contribute to the diseases (Anderson and others [@B2]; Barrett and others [@B8]; Ferguson and others [@B35]; Sato and others [@B97]).

STAT3 Activation in IBD {#s002}
=======================

Constitutive activation of STAT3 in intestinal and peripheral CD4^+^ T cells has been observed in patients with CD, while in UC the lamina propria mononuclear cells and nonimmune colonic epithelial cells show excessive accumulation of activated STAT3 (Lovato and others [@B66]; Mudter and others [@B75]; Li and others [@B64]). The levels of activated STAT3 were also significantly higher in IECs from patients with active UC compared with patients with inactive disease or healthy controls, and these levels correlated with the severity of colitis (Li and others [@B64]). STAT3 is classically associated with mediating cellular survival of IECs, suggesting that the cell population in which STAT3 is constitutively active may dictate the pathology of IBD. A number of studies using mouse models suggest that epithelial Stat3 activation is essential for the maintenance of GI barrier integrity. This has been best demonstrated by the observation that mice with IEC-specific Stat3 deficiency (*Stat3*^ΔIEC^) or IEC-specific deficiency in suppressor of cytokine signaling (Socs)-3, a negative regulator of Stat3 activation (*Socs3*^ΔIEC^), are highly susceptible to IEC injury in the colon following administration of the luminal irritant Dextran Sulfate Sodium (DSS)(Tebbutt and others [@B106]; Rigby and others [@B91]; Bollrath and others [@B15]; Pickert and others [@B83]). Other studies have shown that the deletion of Stat3 in neutrophils and macrophages led to the spontaneous development of enterocolitis, suggesting a protective role for Stat3 in multiple cell subsets within the GI mucosa (Takeda and others [@B105]; Alonzi and others [@B1]). In line with this hypothesis, *Gp130*^Y757F^ mice, which harbor a gp130 knock-in substitution mutation to prevent Socs3-dependent negative regulation and associated systemic ligand-dependent Stat3 hyperactivation, were resistant to acute DSS-induced epithelial damage (Tebbutt and others [@B106]). In response to repeated DSS challenges, however, *Gp130*^Y757F^ mice develop colitis that progresses through to adenoma formation (Putoczki and others, unpublished). It is likely that in these mice excessive, systemic Stat3 activation may favor emergence of a pathogenic cell population because reconstitution of Stat3-deficient CD4^+^CD45RB^hi^ T cells prevented colitis that was observed following transfer of Stat3-proficient cells, and this was associated with a skewing toward nonpathogenic Treg cells rather than the colitogenic Th17 phenotype (Durant and others [@B31]).

Activation of STAT3 by the IL-6 Cytokine Family in IBD {#s003}
======================================================

The Interleukin (IL)-6 family of cytokines comprises 10 members: IL-6, IL-11, ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1), cardiotrophin-like cytokine (CLC), leukemia inhibitory factor (LIF), neuropoietin (NP), oncostatin M (OSM), IL-27, and IL-31. These cytokines share a 4-helix bundle protein structure and signal through a complex of nonsignaling α-receptors (IL-6Rα, IL-11Rα, CNTFRα) that permit interaction with signal-transducing β-receptors (gp130, LIFR, OSMR, IL-27RA, IL-31RA). The unifying feature of this family is the shared use of the transmembrane β-receptor, gp130, either as a homodimer in the case of IL-6 or IL-11 or as a heterodimer used by the other family members. An exception to this is IL-31, which does not utilize gp130, but instead signals through an IL-31RA/OSMR heterodimer.

Upon engagement of their α-receptors, IL-6 and IL-11 mediate formation of a hexameric complex consisting of two ligands, two α-receptors, and two gp130 molecules ([Fig. 1](#f1){ref-type="fig"}). Subsequent phosphorylation of tyrosine residues, by constitutively associated JAKs, on the cytoplasmic tail of gp130 enables activation of the JAK/STAT, MAPK/ERK, and PI3K/AKT pathways (Ernst and others [@B34]). Since gp130 expression is ubiquitous, cellular responses to IL-6 and IL-11 are dependent on tissue-restricted expression of IL-6Rα and IL-11Rα. While membrane-bound IL-6Rα is expressed by nonimmune cells, including IECs, hepatocytes, neutrophils, monocytes, macrophages, and other immune cells, a soluble sIL-6Rα is generated by proteolytic cleavage of membrane-bound IL-6Rα to allow for trans-signaling in any cell that expresses gp130 (Rose-John [@B93]). IL-11Rα is present in 2 isoforms, with the most common, IL-11Rα~1~, being found on epithelial cells of the GI tract, prostate, ovary, endometrium, and other organs, as well as on macrophages, T cells, and hematopoietic cells (Takagi and others [@B104]; Bozza and others [@B16]; Campbell and others [@B19]; Lai and others [@B61]; Cork and others [@B22]; Zurita and others [@B121]; Sales and others [@B95]; Putoczki and others [@B86]). Although, when artificially truncated, IL-11Rα can function as a soluble receptor, this form does not appear to occur naturally (Putoczki and Ernst [@B85]).

![Activation of signaling pathways downstream of interleukin (IL)-6, IL-11, and IL-22. IL-6 and IL-11 signal through a hexameric receptor complex consisting of 2 ligands, 2 IL-6Rα or IL-11Rα receptors, and 2 gp130 receptors, while IL-22 signals through a heterodimeric complex comprising one IL-22RA1 and one IL-10R2 receptor. IL-6 can also signal through soluble IL-6Rα (sIL-6Rα) receptors in cells that do not express the transmembrane IL-6Rα receptor, a process referred to as trans-signaling. Meanwhile, IL-22 binding to its soluble receptor, IL-22RA2, prevents ligand-dependent formation of an activated receptor complex. Following receptor engagement, phosphorylation of tyrosine (Y) residues by JAKs allows for subsequent activation of the STAT, MAPK, and PI3K/AKT pathways. The membrane-proximal tyrosine (Y757 in mouse gp130) in gp130 acts as a docking site for the negative regulator SOCS3, and is also required for activation of MAPK signaling.](fig-1){#f1}

Although *IL6* polymorphisms have been identified in the promoter region (c.-174C/G) as well as in an intron (g.4470G/A) of the human gene and they affect mRNA expression and splicing, these polymorphisms have not been associated with increased susceptibility to IBD (Koss and others [@B55]; Klein and others [@B53]; Cantor and others [@B20]). Likewise, an SNP identified in exon 4 and leading to an amino acid substitution (p.Arg112His) was not associated with increased IBD susceptibility (Klein and others [@B52]). However, a dinucleotide repeat in the *IL-11* promoter region (*IL11.A1* (GT)~7~(CT)~8~) was significantly more abundant in UC patients, although the functional relevance of this repeat was not explored (Klein and others [@B52]).

A significant association between elevated IL-6 expression levels and increased disease activity has been observed in CD and UC patients, with the production of IL-6 and sIL-6Rα by lamina propria mononuclear cells being associated with active disease (Hosokawa and others [@B47]; Mudter and Neurath [@B74]). Meanwhile, IL-11 levels have thus far not been investigated in IBD patients, although elevated IL-11 expression has been observed in a rat model of IBD (Torrence and others [@B107]). Due to its prominent capacity to promote IEC survival and epithelial regeneration, clinical trials with recombinant IL-11 have been undertaken, with a subset of CD patients showing reduced disease severity (Sands and others [@B96]; Herrlinger and others [@B46]).

The contribution of IL-6 and IL-11 to the pathogenesis of IBD has been studied extensively in various mouse models. Loss of IL-6 expression is associated with increased damage to the epithelium and inflammation in the DSS-induced colitis model (Tebbutt and others [@B106]; Grivennikov and others [@B42]). Interestingly, in *Il6*^KO^ mice with increased DSS-induced disease, the colonic inflammatory cell infiltrate was decreased and was accompanied by elevated IL-10 expression (Naito and others [@B76]). Similarly, treatment of mice with a neutralizing IL-6Rα antibody was effective in reducing the severity of inflammation in the CD4^+^CD45RB^hi^ T cell transfer model of colitis, in the spontaneous colitis observed in IL-10-deficient mice, and in the trinitrobenzene sulphonic acid (TNBS) model of CD (Atreya and others [@B4]). A decrease in colitis severity was also observed in transgenic mice that express sgp130 to specifically bind to the IL-6/sIL-6Rα complex and abrogate trans-signaling (Becker and others [@B10]). Similarly, therapeutic administration of sgp130 as an Fc-fusion protein was also effective in reducing spontaneous intestinal inflammation observed in SAMP1/Yit mice and following DSS-induced colitis in wild-type mice (Atreya and others [@B4]; Mitsuyama and others [@B72]).

Compared with IL-6, the contributions of IL-11 to the pathogenesis of IBD are less well understood. However, treatment of mice or rats with recombinant IL-11 ameliorates intestinal inflammation and mucosal damage in various models of IBD (Qiu and others [@B88]; Peterson and others [@B81]; Gibson and others [@B39]). Likewise, in other models of intestinal injury, including radiation, ischemic bowel necrosis, and chemotherapy, administration of recombinant IL-11 reduced epithelial damage and promoted the regenerative response (Orazi [@B77]; Du and Williams [@B26]; Yang and others [@B115]).

Activation of STAT3 by the IL-10 Cytokine Family in IBD {#s004}
=======================================================

The IL-10 family of cytokines comprises IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28A, IL-28B, and IL-29 (Sabat [@B94]). These cytokines share a common 6 α-helical structure and signal through a heterodimeric receptor complex consisting of an R1 receptor (IL-10R1, IL-20R1, IL-22RA1, or IL-28R1) and an R2 receptor (IL-10R2 or IL-20R2) (Ernst and others [@B34]). While X-ray crystallography has demonstrated that IL-10 forms a dimer, IL-19, IL-20, IL-22, IL-24, and IL-28 are secreted as monomers (Ouyang and others [@B79]). Interestingly, dimeric and monomeric forms of secreted IL-26 have been reported (Knappe and others [@B54]; Corvaisier and others [@B23]). For the majority of these cytokines, signal transduction involves IL-10R2, with the exception of IL-19, IL-20, and IL-24, which utilize IL-20R2 (Dumoutier and others [@B28]). While IL-10 signals through a tetrameric complex consisting of two IL-10R1 and IL-10R2 receptor chains each, IL-22 signals through a heterodimeric receptor complex consisting of one IL-22R1 and IL-10R2 chain ([Fig. 1](#f1){ref-type="fig"}) (Kotenko and others [@B57]; Jones and others [@B50]).

While the IL-10R1 and IL-22R1 chains associate with Jak1 (Sabat [@B94]), the common IL-10R2 chain binds to the JAK family member, Tyk2. Phosphorylation of conserved intracellular tyrosine residues in these chains provides docking sites for Stat3 and, to a lesser extent, Stat1 and Stat5 (Lejeune and others [@B62]). Interestingly, Stat3-dependent gene transcription in response to IL-22 can also occur through interaction of the coiled-coil domain of Stat3 with the C-terminal region of IL-22RA1 (Dumoutier and others [@B27]). IL-22 has also been shown to activate the MAPK pathway through ERK, p38, and Jnk (Lejeune and others [@B62]). The presence of a soluble IL-22 receptor (referred to as IL-22RA2 or IL-22BP) with high binding affinity toward IL-22 serves a regulatory role by sequestering cytokines from binding to the transmembrane receptor complex ([Fig. 1](#f1){ref-type="fig"}) (Dumoutier and others [@B29]; Kotenko and others [@B56]; Jones and others [@B50]). While IL-10R2 expression is ubiquitous, IL-10R1 expression is limited to immune cells, including macrophages, T cells, B cells, and NK cells, as well as to cells in the bone marrow (Wolk and others [@B113]; Wolk and others [@B114]; Zenewicz and others [@B118]). By contrast, IL-22R1 expression is limited to nonimmune cell populations, including IECs, skin keratinocytes, subepithelial myofibroblasts, hepatocytes, and bronchial epithelial cells (Dumoutier and others [@B30]; Wolk and others [@B114]; Andoh and others [@B3]; Aujla and others [@B5]; Zenewicz and others [@B118]).

Gene polymorphisms have been identified in components of the IL-10 and IL-22 signaling complexes that correlate with IBD susceptibility. A polymorphism in *IL10* (rs3024505) downstream the 3′ UTR region is associated with increased disease risk for UC and CD and has been suggested to affect regulation of *IL-10*, potentially through the transcription factor AP-1 (Franke and others [@B37]; Franke and others [@B38]). Loss-of-function mutations in *IL10R1* (p.Gly141Arg, p.Thr84Ile) and *IL10R2* (p.Trp159X) were identified in early onset IBD patients and were associated with impaired anti-inflammatory responses and increased secretion of proinflammatory cytokines, including TNFα, IL-1β, IL-6, and sIL-6Rα (Glocker and others [@B41]). In patients with active CD and UC, serum IL-10 concentrations were increased and found to correlate with disease severity and with the production of IL-10 by lamina propria T cells in UC patients with active disease (Kucharzik and others [@B58]; Melgar and others [@B70]). Similarly, IL-22 expression is elevated in patients with active IBD, which has been associated with increased cytokine production in CD4^+^ T cells (Andoh and others [@B3]; Brand and others [@B17]). In patients with CD, this was associated with an increase in Th17, while depletion of Th22 cells was observed in UC patients (Leung and others [@B63]). So far, few studies have investigated *IL22* polymorphisms in IBD susceptibility; however, since polymorphisms (rs1558744, rs7134599, rs2870946, and c.-429C/T) that are associated with increased UC risk have been identified in the *IL22* gene locus, it is likely that deregulated *IL-22* is also involved in CD pathogenesis (Silverberg and others [@B98]; Chi and others [@B21]).

IL-10 dampens the inflammatory response following intestinal injury. This is best demonstrated in *il10*^KO^ mice, which develop CD4^+^ T cell-mediated spontaneous enterocolitis at 3 months of age (Kühn and others [@B60]; Berg and others [@B12]; Davidson and others [@B25]). In contrast, IL-22 expression is important for maintenance of epithelial barrier integrity with loss of IL-22 resulting in more severe colitis as a result of impaired Stat3 signaling (Pickert and others [@B83]). The production of IL-22 by T cells and ILCs, as well as neutrophils mediates protection from colitis (Zenewicz and others [@B118]; Zindl and others [@B120]). Importantly, the production of IL-22 during disease is dependent on IL-23, which reinforces Th17 cell identity, as well as on Lyn tyrosine kinase, which mediates signaling from pattern recognition receptors as part of the innate immune responses (Eken and others 2013; Zindl and others [@B120]; Bishop and others [@B14]). However, some studies suggest that IL-22 may also have a pathogenic role in colitis, because IL-22 neutralization significantly reduced colon pathology and inflammation in an acute colitis model that depends on innate immune responses (Eken and others 2013). These conflicting results suggest both protective and pathogenic roles for IL-22-mediated Stat3 activation, which may be dependent on the severity of the disease.

Cytokine-Mediated STAT3 Activation Maintains Epithelial Homeostasis {#s005}
===================================================================

Animal models of colitis have demonstrated both protective and pathogenic roles for IL-6, IL-11, and IL-22 in IBD through regulation of the innate immune response, epithelial cell proliferation and apoptosis, wound repair, and antimicrobial defense. Below we compare the pathogenic and protective attributes of these cytokine-signaling pathways in the context of epithelial Stat3 activation.

During the initial onset of injury in inflammatory intestinal diseases, IL-6 can protect from epithelial damage through complementing responses in IECs (Kuhn and others [@B59]). In chemically induced models of colitis, for instance, IL-6 promotes Stat3-dependent induction of proliferative, antiapoptotic, and cytoprotective gene programs, including proliferating cellular nuclear antigen, Bcl-x~L~, and heat shock protein (Hsp)-72 (Grivennikov and others [@B42]) ([Fig. 2](#f2){ref-type="fig"}). However, in *Muc2*^KO^ mice, which spontaneously develop colitis associated with epithelial barrier defects, IECs show elevated expression of the proinflammatory cytokines, IL-6, TNFα, and IL-1β, which may perpetuate chronic inflammation in this model (Bao and others [@B7]). Macrophage-derived IL-6 on the other hand can upregulate expression of Muc1 and downregulate that of Muc2 in colon epithelial cell lines (Li and others [@B65]). In immune cells, Stat3 activation through IL-6 trans-signaling can also promote the survival of lamina propria T cells by inducing expression of antiapoptotic Bcl-2 and Bcl-x~L~ proteins to enable T cell survival and perpetuation of sustained inflammation in CD (Atreya and others [@B4]). Collectively, these results demonstrate that during intestinal inflammation, IL-6 can confer both IEC-specific protective and immune cell-mediated pathogenic effects.

![Production of IL-6, IL-11, and IL-22 in inflammatory bowel disease (IBD) and Cancer. The receptors for IL-6, IL-11, and IL-22 are expressed on the surface of intestinal epithelial cells (IECs), and during normal tissue homeostasis, low levels of IL-6, IL-11, and IL-22 are produced by IECs and immune cells. In IBD, epithelial barrier defects result in aberrant activation of the immune system with infiltration of inflammatory cells and increased production of inflammatory cytokines. Among these, IL-11 and IL-22 induce Stat3-dependent gene expression in IECs that confer a proliferative, antiapoptotic, and antimicrobial response. In addition to these protective effects, IL-6 can also sustain survival of pathogenic T cells. IBD patients have an increased risk of colon cancer development with IL-6, IL-11, and IL-22 also associated with the survival and growth of tumorigenic cells, highlighting a delicate balance between beneficial and pathogenic IEC Stat3 activation.](fig-2){#f2}

Similar to chemical models of colitis, expression of IL-6 by colonic IECs and macrophages or of IL-22 by DCs, ILC3, and γδ T cells helps protect against infection by pathogenic bacteria, including *Citrobacter rodentium* (Dann and others [@B24]; Zheng and others [@B119]; Mielke and others [@B71]). As a consequence of Stat3 activation, these cytokines mediate cellular protection through expression of antiapoptotic genes in IECs, including *Bcl-x*~*L*~, *Mcl-1*, *cIAP-2*, and *Bcl-3*, and these effects were no longer observed in *Il6*^KO^, *Il22*^KO^, or *Il22ra1*^KO^ mice or after administration of the corresponding neutralizing antibodies, resulting in increased epithelial damage and inflammation and associated mortality (Dann and others [@B24]; Zheng and others [@B119]; Pham and others [@B82]). Consistent with these findings, Stat3-depedent expression of IL-22 is required for the production of S100A8, S100A9, Reg3β, and Reg3γ by IECs to confer antimicrobial protection. Accordingly, decreased expression of these cytokines attenuates epithelial cell restitution and the general recovery response to infection and chemically induced colitis (Zheng and others [@B119]; Sokol and others [@B99]; Backert and others [@B6]; Guo and others [@B44]).

IL-22 is critical for disease resolution in DSS-induced colitis through Stat3-dependent signaling, resulting in induction of mucus components, Muc1, Muc3, Muc10, and Muc13, as well as antimicrobial peptide secretion from neutrophils (Sugimoto and others [@B103]; Zindl and others [@B120]). Accordingly, loss of IL-22 resulted in severe colitis and this was reverted in response to *IL-22* gene delivery (Sugimoto and others [@B103]). By contrast, this protective effect is abolished upon *IL-22BP* gene delivery. Mucins and, in particular, Muc2 are essential for protection of the epithelium, with Muc2 deficiency resulting in spontaneous disease that is associated with increased IL-22 expression and Jak/Stat signaling, presumably as a compensatory protective measure (Bergstrom and others [@B13]; Lu and others [@B67]). As discussed above for other Stat3-activating cytokines, IL-22 also mediates a tissue repair response in IECs through Stat3-dependent expression of Mcl1, Survivin, Myc, Reg3β, Pla2g5, and Smo (Pickert and others [@B83]). In addition to Stat3, the transcription factor, aryl hydrocarbon receptor (AhR), can synergistically promote the expression of IL-22 expression in ILCs and T cells to mediate protection during intestinal damage and infection (Yeste and others [@B116]). Accordingly, AhR-dependent induction of IL-22 was effective in ameliorating inflammation in TNBS-induced colitis in mice (Monteleone and others [@B73]).

The mechanism by which IL-11 reduces susceptibility to, and extent of, colitis is less well characterized; however, given that recombinant IL-11 can ameliorate symptoms of colitis in numerous animal models and induce Stat3 signaling through engagement of the Gp130 receptor complex, IL-11 is also likely to regulate the expression of genes that are important in the repair response (Gibson and others [@B39]). These involve Reg3β and Reg3γ, vascular endothelial growth factor, and others (Putoczki and others [@B86]). Thus, IL-11 has a dual effect by inducing proliferation of IEC progenitor and stem cells in response to, for instance, 5-fluorouracil-induced intestinal injury, while prophylactic IL-11 administration protects from cytotoxic injury (Potten [@B84]). Additionally, IL-11 was effective in reducing symptoms of mucositis during chemotherapy and mediated protection during oxidative stress through induction of Hsp25 and other cytoprotective proteins in IECs (Gibson and others [@B40]; Ropeleski and others [@B92]). Collectively, these results suggest that IL-11 affords amelioration of intestinal inflammation through induction of proliferative, antimicrobial, and cytoprotective genes.

IL-6, IL-11, and IL-22: New Therapeutic Opportunities for IBD? {#s006}
==============================================================

Given the potential for IL-6, IL-11, and IL-22 to mediate protective effects on IECs through epithelial Stat3 expression and the induction of proliferative, antiapoptotic, antimicrobial, and wound healing genes to maintain epithelial barrier integrity, these cytokines may represent therapeutic opportunities for IBD. However, the relative clinical benefit of each of these cytokines needs to be considered in two important areas of what could be considered as on-target side effects. The first limitation arises from the capacity of some of these cytokines to also confer activities on inflammation-perpetuating immune cells, and the second limitation is in the context of their capacity to promote survival and proliferation of neoplastic epithelium at sites of primary and secondary tumors.

Given the widespread activity of IL-6 on immune cells, its therapeutic use may be limited, since IL-6 can perpetuate colitis by promoting the survival of pathogenic T cells during chronic inflammation (Atreya and others [@B4]; Becker and others [@B10]; Mitsuyama and others [@B72]), although administration of recombinant IL-6 was sufficient to protect IECs during acute intestinal injury by induction of cytoprotective genes, Hsp70 and Bcl-x~L~ (Spehlmann and others [@B101]). Moreover, continuous IL-6 production is observed in mouse models of colitis-associated cancer (CAC) and facilitates Stat3-dependent survival of tumorigenic epithelial cells and T cells (Becker and others [@B10]). This most likely occurs through IL-6 trans-signaling, since recombinant Hyper-IL6, a designer peptide where IL-6 is fused to the sIL-6Rα, but not recombinant IL-6, increased CAC-associated tumor burden (Becker and others [@B10]; Grivennikov and others [@B42]).

Compared with IL-6, IL-11 may have a more favorable range of target cells in particular since megakaryocytes, the main hematopoietic cell target for IL-11, are less likely to play a major role during colitis. In addition, the IL-11-responsive IECs may include stem cells that do respond to IL-6 trans-signaling, but not to IL-6 (Putoczki and others [@B86]). Thus, Stat3-dependent gene transcription in IECs in response to administration of recombinant IL-11 is effective in reducing colitis severity (Gibson and others [@B39]). Additionally, recombinant IL-11 is also able to protect the epithelium during other forms of intestinal injury, including chemotherapy, radiation, and ischemic necrosis (Orazi [@B77]; Du and Williams [@B26]; Yang and others [@B115]). However, we have demonstrated that IL-11 is also the prominent cytokine that drives Stat3-dependent gastric tumor formation (Ernst and others [@B33]) and colon tumorigenesis in the CAC model by acting on radioresistant mutant IECs (Putoczki and others [@B86]). The latter resulted in suppression of the Bcl-2 survival antagonist, Bim, and induction of the cell cycle regulators, cyclin D1, D2, and D3, alongside a range of genes that promote tumor cell invasion (Putoczki and others [@B86]). In the context of CAC tumorigenesis, the latter activities could be reversed following administration of the IL-11 mutein signaling antagonist (Putoczki and others [@B86]).

The directed activity of IL-22 as a cytokine produced by ILCs and other immune cells, but acting primarily on epithelial cells, is an attractive mechanism to therapeutically exploit, notwithstanding some contextual discrepancies outlined above with respect to the capacity of IL-22 to affect progression of colitis. Additionally, IL-22 expression by Th17 cells mediates protection in a mouse model of hepatitis (Zenewicz and others [@B117]). IL-22 also exerts a proinflammatory effect in keratinocytes with transgenic IL-22 mice displaying epidermal thickening and infiltration of macrophages, resembling psoriasis-like inflammation (Wolk and others [@B112]). These changes may be due to IL-22-induced expression of hyperproliferative genes (keratin 14) and inflammatory chemokines (CCL3, CXCL3) (Van Belle and others [@B108]). Interestingly, *Il22*^KO^ mice in the CAC model develop increased tumor burden, suggesting that the exacerbated colitis observed in these mice arising from IL-22 deficiency in the early stage of this model may trigger accelerated tumorigenesis at later stages (Huber and others [@B48]). Meanwhile, IL-22-dependent induction of the antimicrobial peptides, Reg3γ, Reg3β, and S100A8, may trigger dysbiosis and colonization of the intestine with colitogenic microflora such as *Helicobacter hepaticus* (Kirchberger and others [@B51]; Behnsen and others [@B11]). The latter, associated with epithelial barrier defects, which arise in response to oncogenic mutations in IECs, may result in production of proinflammatory cytokines (Grivennikov and others [@B43]). Aberrant IL-22 production by ILCs can also promote tumorigenesis through Stat3-dependent transcription in malignant IECs of cell cycle regulators, including cyclin D1. Likewise, *Il22bp*^KO^ mice had increased CAC-induced tumor burden, while *Il22* gene deficiency reduced tumor burden in the *Apc*^min^ model of intestinal tumorigenesis, demonstrating that dysregulated IL-22 signaling can promote tumorigenesis (Huber and others [@B48]).

Conclusions {#s007}
===========

Maintenance of epithelial barrier integrity is critical for intestinal homeostasis. Perturbation of this leads to aberrant immune activation in response to the intestinal microbiota and, as a consequence, results in autoimmune conditions, including IBD. Stat3 induction of proliferative, antimicrobial, and cytoprotective genes by cytokines, such as IL-6, IL-11, and IL-22, is important for maintenance of intestinal homeostasis. Therefore, and notwithstanding the potential of these cytokines to support tumor formation, there is a strong mechanistic rationale to consider the possibility of exploiting these cytokines therapeutically to ameliorate colitis and reestablish epithelial barrier integrity.
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